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*M A Tichomirowa, M Lee and A Barlier contributed equally to this work.AbstractFamilial isolated pituitary adenoma (FIPA) occurs in families and is unrelated to multiple endocrine
neoplasia type 1 and Carney complex. Mutations in AIP account only for 15–25% of FIPA families.
CDKN1B mutations cause MEN4 in which affected patients can suffer from pituitary adenomas.
With this study, we wanted to assess whether mutations inCDKN1B occur among a large cohort ofEndocrine-Related Cancer (2012) 19 233–241
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AIP mutation-negative FIPA kindreds. Eighty-eight AIP mutation-negative FIPA families were
studied and 124 affected subjects underwent sequencing of CDKN1B. Functional analysis of
putative CDKN1B mutations was performed using in silico and in vitro approaches. Germline
CDKN1B analysis revealed two nucleotide changes: c.286AOC (p.K96Q) and c.356TOC
(p.I119T). In vitro, the K96Q change decreased p27 affinity for Grb2 but did not segregate with
pituitary adenoma in the FIPA kindred. The I119T substitution occurred in a female patient with
acromegaly. p27I119T shows an abnormal migration pattern by SDS–PAGE. Three variants
(p.S56T, p.T142T, and c.605C36COT) are likely nonpathogenic because In vitro effects were not
seen. In conclusion, two patients had germline sequence changes in CDKN1B, which led to
functional alterations in the encoded p27 proteins in vitro. Such rare CDKN1B variants may
contribute to the development of pituitary adenomas, but their low incidence and lack of clear
segregation with affected patients makeCDKN1Bsequencing unlikely to be of use in routine genetic
investigation of FIPA kindreds. However, further characterization of the role ofCDKN1B in pituitary
tumorigenesis in these and other cases could help clarify the clinicopathological profile of MEN4.Endocrine-Related Cancer (2012) 19 233–241Introduction
Among primary central nervous system tumors,
pituitary tumors are the second most frequent by site
(14.3%) and the third most frequent (13.1%) general
group by histology (CBTRUS 2011). Cross-sectional
studies reveal that clinically relevant pituitary adeno-
mas are quite prevalent, occurring in approximately
one in 1064–1288 of the general population (Daly et al.
2006b, Fernandez et al. 2010). Although usually
histologically benign, these tumors have a significant
burden in terms of disease effects (hormonal excess/
deficiency and mass effects) and treatment (neurosur-
gery, biological medical therapy, and radiotherapy). In
the case of genetic syndromes with a known pituitary
adenoma predisposition, such as multiple endocrine
neoplasia type 1 (MEN1) and Carney complex (CNC),
mutation screening and clinical surveillance can aid
early diagnosis. Familial isolated pituitary adenoma
(FIPA) is a clinical syndrome unrelated to MEN1 and
CNC (Daly et al. 2006a). Aryl hydrocarbon receptor
interacting protein (AIP) gene mutations were shown
by Vierimaa et al. (2006) to be associated with a low-
penetrance familial form of pituitary tumors. However,
AIP mutations explain only 15–25% of FIPA cases
(Daly et al. 2007) and 12% of macroadenomas in
young adults (Tichomirowa et al. 2011), the remaining
cases have no currently identified genetic cause.
Among other syndromic conditions associated with
pituitary adenomas is MEN4, which was originally
described in a rat model that spontaneously developed a
MEN1-like condition of neuroendocrine tumors (Fritz
et al. 2002, Pellegata et al. 2006). In humans, as in rats,
this is caused by mutation in the cyclin-dependent
kinase inhibitor 1B (CDKN1B) gene that encodes p27
(IFI27), a cyclin-dependent kinase (CDK) inhibitor.
Mutations in this and other CDKs can be associated234with very rare cases of multiple endocrine tumorigen-
esis (Georgitsi et al. 2007a, Agarwal et al. 2009,
Molatore et al. 2010). Interest in the role of CDKN1B
mutations in other endocrine-related cancer has risen,
with a recent study showing that 2/86 sporadic
parathyroid adenoma patients had germline CDKN1B
mutations, which, in turn, affected p27 protein levels or
stability (Costa-Guda et al. 2011). Apart from endocrine
neoplasia, CDKN1B mutations may also play a role in
primary ovarian failure (Ojeda et al. 2011).
To date, large studies have not examined whether
CDKN1B genetic variants play a role in the patho-
genesis of FIPA kindreds that are negative for AIP
mutations. We therefore performed a genetic sequen-
cing and in vitro characterization study of CDKN1B
gene variants in a large group of 88 well-characterized
FIPA families with normal AIP sequences.Materials and methods
Subjects
The study was performed in 88 FIPA families from
France, Belgium, Italy, Brazil, Spain, Argentina,
Germany, and Bulgaria. FIPA kindreds were defined
as families with two or more related persons having
pituitary adenomas without clinical or genetic evi-
dence of MEN1 or CNC. AIP mutations were excluded
from all FIPA kindreds by sequencing and multiplex
ligation-dependent probe amplification.
The FIPA cohort consisted of 1 four-member,
3 three-member, 39 two-member homogeneous, and
45 two-member heterogeneous FIPA families. The
four-member family presented with one corticotropi-
noma, one prolactinoma, and two somatotropinomas
and the three-member family presented with two
somatotropinomas and one nonfunctioning pituitarywww.endocrinology-journals.org
AUTHOR COPY ONLYEndocrine-Related Cancer (2012) 19 233–241
adenoma. The 39 two-member homogeneous families
had prolactinomas (nZ23), somatotropinomas
(nZ12), corticotropinoma (nZ2), gonadotropinoma
(nZ1), and nonfunctioning pituitary adenoma (nZ1)
in the affected members. From the total of 181 FIPA
patients, 124 were available for genetic testing.
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki, approved by
Ethics Committee of the University of Lie`ge, and all
subjects provided informed written consent in their
own language for the genetic screening.CDKN1B genetic analysis and genotyping
Genomic DNA was isolated from blood samples from
at least one affected member of each FIPA family. The
structure of CDKN1B was based on Ensembl
sequences ENSG00000111276. The primers used for
the analysis (two sets of primers were used to amplify




CAGGATTGTGGGTG; and Ex2R, CCCAGCCTTC-
CCCATTGC. Each 25 ml PCR reaction contained
140 ng genomic DNA, 1.25 ml of each primer,
1.5 mM MgCl2, 10 mM Tris–HCL buffer (pH 8.3),
200 mM dNTPs, and 1.25 U FastStart Taq polymerase
(Roche). PCR conditions were 95 8C for 10 min,
followed by 35 cycles of 30 s at 95 8C, 45 s at 65 8C,
30 s at 72 8C, finishing with 7 min at 72 8C. PCR
products were sequenced using ABI3130XL and
BigDye Terminator v3.1 technology (Applied Biosys-
tems, Foster City, CA, USA).
A group of control samples from normal individuals
(nZ476) were studied to assess CDKN1B allelic
frequencies compared with FIPA patients. These
samples were derived from 326 Italian, 100 Belgian,
and 50 French subjects. To explore the status of a
variant discovered in a Brazilian family, further
genotyping for this specific change was performed in
100 healthy subjects from Brazil.Reagents
Cell culture materials were purchased from Life
Technologies (Karlsruhe, Germany), Nunc (Wies-
baden, Germany), and Sigma. Inhibitors for protein
kinases A/G/C, staurosporine, H8, and H89 were
purchased from Biaffin (Kassel, Germany). The protein
synthesis inhibitor cycloheximide (CHX) and the
proteasome inhibitor MG132 were purchased from
Sigma.www.endocrinology-journals.orgExpression vectors, cell lines, and transfections
The p27K96Q and p27I119T mutations were introduced
by site-directed mutagenesis (Quikchange II Site-
Directed Mutagenesis Kit; Stratagene, Waldbronn,
Germany) in the wild-type human CDKN1B cDNA
cloned in a pYFP and pHA backbone as described
previously (Pellegata et al. 2006). MCF7 and HeLa
cells (LGC Standards, Wesel, Germany) were main-
tained in RPMI 1640 and DMEM medium, respect-
ively, supplemented with 10% FCS, 20 mM L-
glutamine, 100 units/ml penicillin G sodium, and
100 mg/ml streptomycin sulfate. GH3 cells (ATCC)
were grown in F12 medium supplemented with 15%
horse serum, 2.5% FCS, 20 mM L-glutamine, 100
units/ml penicillin G sodium, and 100 mg/ml strepto-
mycin. Transient transfection was performed as
described previously (Pellegata et al. 2006).Drug treatments and pull-down assays
HeLa cells transfected with HA-p27-wt or HA-p27I119T
were treated with 2 nM staurosporine, 2 mM H8, and
2 mM H89 for 24 h. To determine p27 half-life, GH3 cells
that transfected the YFP-p27-wt, YFP-p27K96Q, or
YFP-p27I119T were treated with 25 mg/ml CHX for the
indicated times or with 20 mM of the proteasome
inhibitor MG132 for 5 h. Cell lysates were prepared,
separated, and blotted using standard procedures as
described previously (Pellegata et al. 2006). Primary
antibodies used were anti-p27 monoclonal antibody (BD
Biosciences, Heidelberg, Germany), antiphospho p27
(Thr187; Santa Cruz Biotech, Santa Cruz, CA, USA), and
a-tubulin (Sigma).
HeLa cells transfected with YFP-p27-wt or YFP-
p27K96Q for 24 h were lysed in ice-cold buffer (5 mM
EDTA and 1% Triton-X100). Total protein (500 mg)
was pulled down with 5 mg Grb2-GST recombinant
protein already bound to 2.5 ml glutathione agarose
beads (Upstate, Charlottesville, VA, USA). After
extensive washing, immunoprecipitates were resus-
pended in 25 ml Laemmli buffer. Immunoblotting was
performed using the anti-p27 and subsequently the
anti-Grb2 antibodies (Santa Cruz Biotech).Immunofluorescence
Immunofluorescence was performed on MCF7 cells
transfected with p27-wt, p27K96Q, or p27I119T on a
coverslip; 24 h later, transfected cells were fixed in
2% paraformaldehyde in PBS for 30 min at room
temperature. Cell nuclei were stained with 1 mg/ml
Hoechst for 5 min at room temperature and mounted
on glass slides. Images were generated using a Zeiss235
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Axiovert 200 epifluorescence microscope including an
Apotome unit (Zeiss, Jena, Germany) using the YFP
and the DAPI channel and processing was carried out
using Zeiss computer software (AIM 3.2).
In silico analysis
To predict splice signals, the following programs were
used: SpliceView (http://bioinfo.itb.cnr.it/oriel/splice-
view.html and http://www.fruitfly.org/seq_tools/
splice.html). The web-based ESEfinder 3.0 program
(available at: http://rulai.cshl.edu/cgi-bin/tools/ESE3/
esefinder.cgi) searches for sequences that act as
binding sites for four members of the serine/arginine-
rich family of splicing enhancer proteins. Input
sequences were screened for consensus-binding
sequences for the SR proteins SF2/ASF (SRSF1),
SC35 (SRSF2), SRP40 (SRSF5), and SRP55 (SRSF6),
developed using the SELEX (systematic evolution of
ligands by exponential enrichment) procedure.
Increased threshold values of 2.5 for SF2/ASF (from
1.956) and 3.0 for SC35 (from 2.383), SRP40 (from
2.670), and SRP55 (from 2.676) were used in order to
minimize false-positive results.Results
CDKN1B sequencing
Genetic sequencing in the CDKN1B gene revealed two
heterozygous allelic variants, one that did not occur in the
control population, i.e. c.286AOC (p.K96Q), and one
that occurred at a very low frequency, c.356COT
(p.I119T; 1/476, 0.2% of healthy controls). Two other
variants were detected in the matching control popu-
lations: p.S56T (c.167GOC) and p.T142T (c.426GOA).
























Figure 1 Subcellular localization of wild-type and mutant p27. (A) H
p27-wt, p27K96Q, or p27I119T mutant proteins and examined by weste
mutant transfected cells. (B) MCF7 cells were transfected as in (A
proteins (wild-type and mutants) were located primarily in the nucle
236both brothers of a Brazilian two-member heterogeneous
FIPA family with a somatotropinoma and a nonfunction-
ing pituitary adenoma and appeared among 100 Brazilian
controls: 198 chromosomes were G and two were C
(genotype: 196 G/G and two G/C). An intronic change,
c.605C36COT, was seen in one FIPA family member
(male with a giant prolactinoma) and did not occur in
the control subjects; however, in silico modeling
indicated that this variant had no strong effect on splicing
and was deemed to probably represent a nonpathological
change. The previously reported T142T (c.426GOA)
variant was found in three unrelated prolactinoma
patients (one male and two females) across three different
FIPA families. The findings from the genotyping of the
control cohort (nZ476 healthy individuals) were as
follows: c.286AOC (p.K96Q), all 952 chromosomes
were A; c.605C36COT, all 952 chromosomes were C;
c.356TOC (p.I119T), 950 chromosomes were T and one
chromosome was C (genotype: 950 T/T and one T/C);
c.426GOA (p.T142T), 945 chromosomes were G and
seven chromosomes were A (genotype: 945 G/G
and seven G/A).
The I119T change was found in one member of a two-
person homogeneous FIPA family with somatotropino-
mas. The other affected member could not be genetically
tested (Supplementary Figure 1, see section on supple-
mentary data given at the end of this article). The K96Q
variant was found in a homogeneous FIPA family
presenting with prolactinomas, but the variation did not
segregate with prolactinoma-affected patients. The
patient with the K96Q change had hyperprolactinemia
due to a suspected prolactinoma that was treated
chronically with cabergoline when referred, who also
developed breast cancer at the age of 41. The unaffected
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Figure 2 Stability of wild-type and mutant p27. The rate of the turnover of p27-wt, p27K96Q, and p27I119T proteins was measured
in exponentially growing, transiently transfected GH3 cells using cycloheximide (CHX) with and without the proteasome inhibitor
MG-132. p27-wt and p27K96Q have a half-life ofw10 h in GH3 cells. MG-132 has no effect on p27K96Q degradation. In contrast,




























Figure 3 GST-Grb2 pull-down assay with p27K96Q. HeLa cells
were transfected with p27-wt-YFP and p27K96Q-YFP. Cell
lysates (INPUT) were incubated with recombinant GST-Grb2.
After washing the Grb2-GST resin, all the bound proteins (IP)
were eluted. The SDS–PAGE was loaded with 50 mg of input
and the whole IP. Immunoblotting was performed as described
previously with anti-p27 antimouse antibody and subsequently
with anti-Grb2 antirabbit antibody. As shown, little p27K96Q-YFP
was pulled down compared with p27-wt. p27K96Q has a reduced
affinity for Grb2 binding.
Endocrine-Related Cancer (2012) 19 233–241In vitro analysis of mutant p27 proteins
The subcellular localization, stability, and function of
the K96Q and I119T mutant proteins were studied
in vitro. To determine the effect of the p27 changes on
protein localization and stability, the following YFP-
tagged proteins were generated: p27-wt, p27K96Q, and
p27I119T. Transient transfections performed in MCF7
cells revealed that the mutant proteins are expressed at
similar levels (Fig. 1A). Both wild-type and mutant
p27 proteins localize to the nucleus (Fig. 1B). We
noted that the p27I119T protein migrates slower than
p27-wt by SDS–PAGE (Fig. 1A).
As previously reported MEN4-associated CDKN1B
mutations often affect the stability of the encoded p27
protein, we analyzed the turnover of p27K96Q and
p27I119T in exponentially growing, p27-negative GH3
cells. We blocked de novo protein synthesis with CHX,
and at various time points thereafter, we analyzed the
amount of p27-wt, p27K96Q, and p27I119T. We
observed a time-dependent reduction of p27-wt and
p27K96Q following CHX treatment, while p27I119T
levels did not decrease throughout the experiment
(Fig. 2). These results show that the p27I119T protein is
more stable in vitro than p27-wt. Although the
intracellular amount of p27 is mainly regulated by
ubiquitin-mediated proteasomal degradation, inhibit-
ing the proteasome has been shown to stabilize p27
(Pagano et al. 1995). Proteasome inhibition of
transfected GH3 cells by MG-132 partially recovered
p27-wt but not p27K96Q or p27I119T proteins (Fig. 2),
indicating that the mutant p27 proteins are resistant to
proteasome degradation.
The K96Q missense change is situated in the
proline-rich domain (amino acids 90–96) of p27. This
domain mediates the binding of p27 to the adaptor
protein GRB2, an interaction that eventually leads to
p27 degradation. In a pull-down assay using anti-Grb2
antibody, p27K96Q displayed reduced Grb2 binding
compared to p27-wt (Fig. 3), and this may bewww.endocrinology-journals.orgresponsible for the observed proteasome resistance of
this mutant p27 protein.
As already mentioned, p27I119T migrates more slowly
than p27-wt by SDS–PAGE (Fig. 1A). To exclude that
this abnormal migration pattern could be an artifact of
the cloning, we subcloned both p27-wt and p27I119T
cDNA into a different vector (having an HA tag) and
checked the expression of the proteins upon transfection
in GH3 and HeLa cells. Western blotting analysis
showed that HA-tagged p27I119T also migrated more
slowly than HA-tagged p27-wt (Fig. 4A).
B lymphocytes from the variant-positive patient
grown in culture were available and were analyzed for
p27 expression. We observed the presence of two
bands by western blotting, one corresponding to the
wild-type allele and one to the I119T mutant protein
migrating gradually in the gel (Fig. 4B). Thus, p27I119T
is expressed in vivo in the patient’s blood.
p27 is a target of phosphorylation at various
residues, and these posttranslational modifications
regulate its function, stability, and intracellular local-
ization (reviewed in Vervoorts & Lu¨scher (2008)).237
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Figure 4 p27I119T is associated with abnormal SDS–PAGE migration. Western blotting analysis of the whole lysates from p27-
wt-HA- or p27I119T-HA-transfected GH3 cells (A) and lymphoblastoid B cell of p27I119T mutation carrier (B). (C) HeLa cells were
transfected with p27-wt-HA and p27I119T-HA constructs. After 24 h, cells were incubated for 6 h in a culture medium supplemented
with a pool of protein kinase inhibitors (staurosporine, H89, and H8) or left untreated. (D) Scheme of the mutations introduced at the
isoleucine 119 residue. (E) HeLa cells were transfected with YFP-p27 constructs containing p27-wt, p27I119A, p27I119T, p27I119D, or
p27I119E mutant proteins and examined by western blotting. The altered mobility of all of the I119 variants is evident.
M A Tichomirowa, M Lee, A Barlier et al.: CDKN1B variants in AIP-negative FIPA kindredsTheoretically, increased phosphorylation could explain
the migration shift of p27I119T. To test this possibility,
we transfected HeLa cells with p27-wt or p27I119T and
then treated them with inhibitors of protein kinases A,
C, and G (staurosporine, H8, and H89). We then
checked for alterations in the SDS–PAGE migration
behavior of both proteins, but we did not observe any
differences in the presence or absence of the inhibitors
(Fig. 4C).
To confirm whether the atypical migration of
p27I119T in SDS–PAGE gels is linked specifically to
the isoleucine 119 residue, we substituted I119 with
three different amino acids (Fig. 4D) and analyzed their
migration behavior. We introduced the amino acid Ala
(A) that cannot be phosphorylated at position 119 by
mutagenesis. Upon transfection in HeLa cells, p27I119A
showed the same migration pattern as p27I119
(Fig. 4E). We then substituted I 119 with two238phosphomimetic amino acids (aspartic acid, D;
glutamic acid, E) to generate two mutant proteins,
p27I119D and p27I119E. Surprisingly, these two proteins
showed an even slower migration by SDS–PAGE
compared with p27I119T (Fig. 4E). Thus, genetic
changes that substitute the residue at position 119
of p27 affect the migration pattern of the protein.Discussion
FIPA is a syndrome of pituitary adenomas occurring
in a familial setting in the absence of MEN1 and CNC
(Daly et al. 2006a). Since the discovery by Vierimaa
et al. (2006) that AIP is an inherited cause of pituitary
adenomas in 2006, extensive studies have demonstrated
its involvement in the pathophysiology of 15–25%
of FIPA kindreds (Georgitsi et al. 2007b, Daly et al.
2010, Igreja et al. 2010, Tichomirowa et al. 2011).www.endocrinology-journals.org
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In an effort to study other potential genetic causes of
FIPA, we examined CDKN1B sequences in 124
individuals from 88 FIPA AIP mutation-negative
kindreds, as previous studies had concentrated largely
on MEN1-negative MEN1 cohorts (Igreja et al. 2009).
We found two new germline CDKN1B changes in
patients with pituitary adenomas from AIP mutation-
negative FIPA kindreds. Although these sequence
changes were identified in a familial setting and they
altered p27 function or structure in vitro, the K96Q
variant did not segregate with pituitary adenomas in
one kindred. In the case of I119T variant that affected
CDKN1B molecular weight/migration, one of the two
family members affected with a pituitary adenoma was
not available for genetic testing, so it cannot be fully
ruled in or out as a cause of the clinical phenotype.
Based on these findings, CDKN1B changes alone are
not a frequent or likely cause of the FIPA tumor
phenotype but could represent a contributing factor.
Nevertheless, the CDKN1B sequence variants
described here add to growing evidence of a role for
p27-related dysfunction in the development of a subset
of many endocrine tumors within and outside of the
setting of MEN4.
The involvement of p27 in pituitary tumorigenesis
has been demonstrated in animal studies. Indeed, p27-
null mice develop pituitary intermediate lobe adeno-
mas (Fero et al. 1996, Kiyokawa et al. 1996,
Nakayama et al. 1996), and heterozygous p27C/K
mice display pituitary hyperplasia (Fero et al. 1998).
While human pituitary adenomas only rarely showed
somatic CDKN1B mutations, downregulation of p27 is
observed frequently in these tumors, especially in
corticotropinomas (Kawamata et al. 1995, Ikeda et al.
1997, Jin et al. 1997, Takeuchi et al. 1998). Interest
was renewed by the discovery that germline CDKN1B
mutations in both the rat MENX and the human MEN4
syndromes are associated with development of pitu-
itary adenomas (Fritz et al. 2002, Pellegata et al. 2006).
Among the eight MEN4 patients identified to date,
three (37.5%) had pituitary adenomas (a somatotropi-
noma, Cushing disease, and a nonfunctioning ade-
noma), so it appears to be a distinctive disease feature
among these patients, although not as pronounced as
primary hyperparathyroidism (7/8 patients, 87.5%).
The K96Q mutation is situated in the proline-rich
domain (amino acids 90–96) of p27, which mediates
the binding to the adaptor molecule Grb2, which in turn
recruits and leads to activation of Ras (Marinoni &
Pellegata 2011). The interaction between p27 and Grb2
promotes p27 degradation in the cytoplasm (Pagano
et al. 1995, Vervoorts & Lu¨scher 2008). Indeed,
p27K96Q displayed less Grb2 binding during a pull-www.endocrinology-journals.orgdown assay compared with p27-wt. These findings
echo the altered Grb2 interaction reported by Agarwal
et al. (2009) in a patient with a missense mutation at
the previous amino acid residue (P95S) that led to
parathyroid tumors and a metastatic gastrinoma.
The I119T variant affects a residue located in the
so-called ‘scatter domain’ of p27 (amino acids 118–
158), which is responsible for actin cytoskeletal
rearrangement and cell migration, processes involved
in metastatic spread of human tumors (McAllister et al.
2003). This change causes a shift in the migration of
the p27 protein in SDS–PAGE gels. The unique
migration pattern of p27I119T, indicative of posttransla-
tional modifications, was not affected by multiple
kinase inhibitors, suggesting that it is not due to
phosphorylation at this newly created threonine
residue. As glycosylation occurs at serine, threonine,
or aspartic acid residues, the migration shift associated
with the 119T residue could be caused by glycosylation
of the protein (Dennis et al. 1999), thereby conferring
greater stability. In agreement with this finding,
p27I119T is more stable than the p27-wt in vitro.
The I119T sequence change was previously
described as a somatic genetic mutation in a patient
with myeloproliferative disorder (presence of the
change in the patient’s germline was not studied;
Pappa et al. 2005); also the W76X nonsense CDKN1B
mutation found in a MEN4 patient had been previously
identified as a somatic change in hematological
malignancies (Morose´tti et al. 1995). Moreover, the
c.356T/C (I119T) change has been reported in a study
of hereditary prostate cancer (Chang et al. 2004), but
the association of the C variant allele with the
predisposition to the disease could not be demon-
strated. The observations that this variant allele is
expressed and translated into protein in our mutation
carrier, in addition to the association of the I119T
change with other tumor types and its potential effect in
the function of p27, make a plausible case that it may
play a role in tumor predisposition.
In conclusion, this study is the first extensive study
of CDKN1B germline variants in a set of 88 FIPA
families that do not have AIP mutations. According to
our data, mutations of CDKN1B are not a cause of
FIPA. However, CDKN1B germline variants associ-
ated with in vitro molecular phenotypes were seen in
nearly 2% of cases studied. Altered p27 function may
infrequently play a role in general pituitary disease
outside of MEN4, although screening for CDKN1B
mutations systematically appears unjustified in the
setting of the O75% of FIPA kindreds not caused by
AIP mutations (Jaffrain-Rea et al. 2011).239
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